In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

Sage Therapeutics, Inc.

https://www.sagerx.com

Latest From Sage Therapeutics, Inc.

Finance Watch: CG Oncology, MBX, Jnana Bring In VC Mega-Rounds

Private Company Edition: In the latest round of $100m-plus venture capital financings, CG Oncology, MBX Biosciences and Jnana Therapeutics raised $120m, $115m and $107m, respectively. Also, MVM Partners closed a $500m fund and former Sage CEO leads incubator ABio-X in Massachusetts.

Financing Deals

Reviving A Longsuffering Neuro Company: The Marinus Story

Marinus Pharmaceuticals’ CEO spoke candidly to In Vivo about breathing new life into ultra-rare epilepsy disorder drug ganaxolone.

Strategy Restructuring

Relmada’s Phase III Depression Study Scuppered By ‘Placebo Paradox’

An unexpectedly strong response in the placebo arm has derailed a monotherapy study of Relmada’s investigational antidepressant REL-1017, but the company will continue its trials as an adjunctive therapy.

Neurology Clinical Trials

Biogen Prepares More Doubtful Phase III Results For FDA Scrutiny, This Time In ALS

After the Aduhelm controversy, Biogen has another neurodegenerative disease drug which so far can only show efficacy against surrogate biomarkers – will the FDA be swayed again this time?

Clinical Trials Commercial
See All

Company Information

  • Industry
  • Biotechnology
  • Medical Devices
  • Pharmaceuticals
  • Biotechnology
    • Drug Discovery Tools
      • ADMET
UsernamePublicRestriction

Register